

Special Issue

Multiple Sclerosis: Neuro-Technology and New Approaches for Treatment, Diagnosis and Symptom Monitoring

Message from the Guest Editors

The landscape of clinical care and research in multiple sclerosis (MS) is rapidly evolving. Disease-modifying therapies (DMTs) have improved substantially, with recent promising breakthroughs including BTK inhibitors that target progressive MS phenotypes. Non-pharmacological neuromodulation approaches offer additional promise to enhance the efficacy of both pharmacological and non-pharmacological interventions.

Parallely, recent digital tools have shown transformative potential for diagnosis and disease monitoring. These new technologies can not only improve the ability to diagnose and monitor patients in everyday clinical practice but may also replace conventional endpoints in clinical trials in the future.

This Special Issue invites submissions regarding novel pharmacological treatment strategies and non-invasive neuromodulation in MS. We also welcome submissions exploring biomarkers and digital tools (including, but not limited to, wearable sensors, AI-based imaging analysis, digital cognitive or motor tests, digital patient-reported outcomes) that demonstrate potential to replace conventional MS clinical trial endpoints in the near future.

Guest Editors

Dr. Michelangelo Dini

Department of Neurorehabilitation Sciences, Casa di Cura Igea, Milan, Italy

Dr. Letizia Leocani

Faculty of Medicine, Vita-Salute San Raffaele University, Milan, Italy

Deadline for manuscript submissions

31 July 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/264126

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).